The United States and United Kingdom Sign Tariff-Free Agreement on Pharmaceuticals.

The United Kingdom and the United States have finalized a key commercial pact that will keep zero levies on UK pharmaceutical products being sold in the American market.

The Terms of the Pact

Under the terms of the agreement, the UK has agreed to boost spending on drugs through the National Health Service (NHS). This pledge ensures that import taxes on these crucial products will be held at nothing for a period of three years.

This deal follows earlier threats to dramatically increase import taxes on patented drug imports, with increases floated as high as one hundred percent.

"This deal with the UK strengthens the worldwide climate for innovative medicines and establishes long-overdue equity to transatlantic drug exports," an announcement said.

Trade Impact

Drugs represent one of the the United Kingdom's most significant exports to the United States, which is by far the primary destination for major British pharmaceutical firms.

Export figures indicate that in the one-year period leading up to September, the UK shipped pharmaceutical products worth £11.1bn to the US. This amount accounted for 17.4% of total UK exports in that span.

"This agreement protects work, stimulates funding and sets the stage for the UK to establish itself as a international leader for life sciences," the Business and Trade Secretary stated.

Specific NHS Changes

The pact entails several specific pledges from the United Kingdom:

• Higher Cost Ceiling: The UK will increase the cost ceiling at which it judges new medicines to be prohibitively costly by 25%.
• Boosted Medicine Funding: There is a aim to double overall health service expenditure on drugs from 0.3 percent of Gross Domestic Product to 0.6% over the next decade.
• Rebate Cap: The amount manufacturers must return to the NHS to prevent overspending will be limited at 15%. In the past, refunds were more than twenty percent.

Industry Background

The deal comes amid a long-running dispute between the pharmaceutical industry and the British authorities over spending levels and regulatory access.

The disagreement were heightened by arguments that American patients were charged significantly more for the same drugs than consumers in the other developed nations.

Over the last 18 months, several significant drug company projects in the UK have been halted or abandoned, while multi-billion-dollar expansions have been announced toward US facilities.

One official acknowledged that the NHS needed to spend more on medicines, noting that its spending on drugs had declined as a percentage of its resources over the past decade.